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In Brief Hinson et al. now use human iPS models of PRKAG2 cardiomyopathy combined with engineered cardiac microtissues to reveal key links between metabolic sensing by AMPK and myocyte survival, metabolism, and TGF-beta signaling.
INTRODUCTION
PRKAG2 is one of three regulatory subunits of the AMP-activated protein kinase (AMPK) and is highly expressed in the heart (Lang et al., 2000) . The activity of AMPK is determined physiologically by energy status. Changes in AMPK activity have been observed in acquired forms of cardiac remodeling such as pressure overload (Tian et al., 2001 ) and inherited as autosomaldominant left ventricular hypertrophy (LVH) caused by PRKAG2 missense mutations (Gollob et al., 2001) . In vitro studies indicate that PRKAG2 mutations decrease the nucleotide-dependence of AMPK catalytic activity (Scott et al., 2004) , resulting in gain of function. Once activated, AMPK regulates multiple metabolic pathways including increased glucose uptake by GLUT4 translocation (Kurth-Kraczek et al., 1999) and glycolysis by phosphofructokinase-2 regulation (Marsin et al., 2000) . In addition to its metabolic effects, AMPK regulates diverse energy-dependent cellular functions including protein synthesis, autophagy, cytoskeletal dynamics, and cell polarity (Hardie et al., 2012) .
PRKAG2 mutations are identified in about 1% of patients with unexplained LVH (Murphy et al., 2005) . PRKAG2 cardiomyopathy mimics some features of hypertrophic cardiomyopathy (HCM), a genetic disorder caused by mutations in contractile components of the sarcomere, but with notable differences. HCM, but not PRKAG2, mutations exhibit myocyte disarray and markedly increased fibrosis (Ho et al., 2010) . By contrast, PRKAG2 mutations cause electrophysiologic abnormalities such as atrioventricular conduction disease and mal-development of the annulus fibrosus that predisposes to ventricular pre-excitation (Arad et al., 2002) . Some features of the PRKAG2 cardiomyopathy can be explained by alterations in glucose handling (Kim et al., 2014) , which leads to increased glycogen accumulation in myocytes and LVH (Arad et al., 2002) . Mechanisms for the paucity of myocardial fibrosis in PRKAG2 cardiomyopathy prior to end-stage disease (Pö yhö nen et al., 2015) remain an enigma.
We developed two human in vitro models of PRKAG2 cardiomyopathy to study AMPK function using myocytes (iPS-CMs) differentiated from induced pluripotent stem cells (iPSCs) from patients and by TALEN genome engineering. We analyzed function in myocytes and cardiac microtissue (CMT) assays that better recapitulate cardiac architecture and myocyte maturation (Boudou et al., 2012; Hinson et al., 2015) . We combined these in vitro analyses with mouse models to further probe the mechanisms that distinguish PRKAG2 from HCM mutations.
RESULTS

PRKAG2
Mutations Increase AMPK Activity, Glycogen Accumulation, and AKT Signaling Resulting in iPS-CM Hypertrophy A patient-specific (P-S) iPSC model was engineered from members of a large family (Arad et al., 2002 ) with a heterozygous, missense mutation in PRKAG2 substituting asparagine for isoleucine at residue 488 (N488I). To create P-S iPSCs (Figure 1A) , we reprogrammed T cells from two affected family members (P A N488I/WT and P B N488I/WT ), one unaffected relative ) and unrelated control (P C2
WT/WT ) (circle = female; square = male; shaded = PRKAG2 cardiomyopathy; unshaded = normal heart). P A N488I/WT iPSCs were genome-edited with TALENs and a wild-type PRKAG2 oligonucleotide to create an isogenic series at the N488I locus (P AT N488I/WT , P AT WT/WT , and P AT KO/KO ). Sanger tracings of PRKAG2 amplicons derived from the isogenic TALEN series (red arrow = A/T substitution) are shown.
(B and C) Representative immunoblots (B) probed with anti-p(T172)-AMPKa subunit, p(S79)-ACC, and total AMPKa and ACC and quantified by densitometric analysis (n R 3) (C).
(D) Quantification of intracellular glycogen in iPS-CMs (n R 3). (E and F) IPS-CM size measured by normalized forward scatter (FSC) by flow cytometry (n R 15 differentiations) (E) and by pixel area on fibronectin lines (n R 20 myocytes) (F; left panel); representative myocytes stained with anti-cardiac actinin A (green) and DAPI (blue; the scale bar represents 10 microns) (F; right panel).
(G) Quantification of anti-p(T308)-AKT by normalized densitometry (n R 3 lanes each) of immunoblots from lysates derived from iPS-CMs. The significance was assessed by Student's t test (C-G) and the error bars are mean ± SEM (C-G).
(P C1 WT/WT ) and one unaffected and unrelated control (P C2   WT/WT ). In parallel, we engineered a series of scarless, isogenic iPSC lines derived from P A N488I/WT by electroporation of TALE-nucleases (TALENs) (Ding et al., 2013) with wild-type single-stranded donor oligonucleotide that target sequences flanking the N488I mutation ( Figures 1A, S1A , and S1B). The TALEN isogenic series included an unmodified N488I mutation (P AT N488I/WT ), wild-typecorrected PRKAG2 (P AT WT/WT ), and homozygous null alleles in PRKAG2 (P AT KO/KO ).
IPSCs were then differentiated to iPS-CMs and purified by metabolic selection. Since prior publications reported conflicting effects of N488I on AMPK activity in vivo (Arad et al., 2003; Sidhu et al., 2005) , we initially measured phosphorylation of AMPKa at threonine 172. Both P A N488I/WT and P AT N488I/WT iPS-CMs had similarly increased basal AMPKa phosphorylation compared to controls, while P AT KO/KO has the lowest AMPKa phosphorylation (Figures 1B and 1C) . We deduced that the TALEN isogenic series is a model of gain and loss of function in AMPK activity. We extended these studies to characterize a second AMPK missense mutation, R531Q, which causes profound neonatal PRKAG2 cardiomyopathy (Burwinkel et al., 2005) . Using a lentiviral system, we expressed N488I and R531Q in iPS-CMs. While lenti-N488I increased AMPKa phosphorylation 23 compared to lenti-wild-type (WT) and GFP controls, lenti-R531Q increased AMPKa phosphorylation by over 203 ( Figure 1C , middle panel). N488I also increased acetylCoA carboxylase (ACC) phosphorylation at the AMPK target site serine 79 ( Figure 1C , right panel). These results confirm that N488I and R531Q mutations that cause PRKAG2 cardiomyopathy increase AMPK activity in proportion to the degree of cardiomyopathy severity. Next, we used the TALEN isogenic series to model the consequences of gain and loss of function in AMPK activity. Glycogen content in P AT N488I/WT iPS-CMs was 17% higher than in P AT WT/WT iPS-CMs, while the glycogen content in P AT KO/KO iPS-CMs was the lowest ( Figure 1D ). We analyzed iPS-CM size by flow cytometry and after patterning iPS-CMs onto fibronectin lines to align sarcomeres to more closely resemble in vivo sarcomere structure ( Figures 1E, 1F , and S1J). By either method, N488I iPS-CMs were larger. Mutant iPS-CMs also had increased insulin signaling, a recognized hypertrophic signal, as supported by increased AKT phosphorylation at threonine 308 ( Figure 1G ). These data confirm that LVH associated with PRKAG2 cardiomyopathy correlates with both glycogen accumulation and myocyte hypertrophy that is associated with AKT phosphorylation.
AMPK Increases Microtissue Twitch Force by Enhancing Myocyte Survival
Unlike mutations in beta-myosin heavy chain that cause HCM by altering properties of contractile components (Debold et al., 2007) , whether AMPK regulates cardiac force production remains unknown. To address this, we measured twitch force in CMTs that are composed of iPS-CMs (Movies S1 and S2). P AT N488I/WT CMTs generated 6.16 mN of twitch force compared to 2.81 mN by P AT WT/WT CMTs (p = 1.5 3 10 À6 ; Figure 2A ), an increase that remained after normalization for CMT width ( Figure 2B ). As twitch force in CMTs is dependent on cell composition and maturity, we expressed N488I or GFP by lentiviral transduction into iPS-CMs with identical iPS-CM content and made CMTs. Lenti-N488I similarly increased twitch force by 98% (p = 4 3 10 À5 ; Figure 2C ). Next, iPS-CMTs were stained with the sarcomeric isoform of actinin A and nuclear stain DAPI ( Figure 2D ) to identify structural changes that may explain increased CMT twitch force. Analysis of stained P AT N488I//WT CMTs identified a 51% increase ( Figure 2E ; p = 5.7 3 10 À6 ) in iPS-CM number despite controlling for iPS-CM seeding density. Since single cell traction force assays were not different in iPSCMs with N488I ( Figure S2A ), and expression of maturity and chamber-specific transcript markers were also not regulated by N488I ( Figures S2B-S2E ), we conclude that P AT N488I/WT CMTs have increased iPS-CM number per CMT as the major mechanism for increased CMT twitch force.
To consider whether the increase in iPS-CM number was due to increased iPS-CM survival or proliferation, we stained live CMTs with propidium iodide (PI), which penetrates and binds DNA only in non-viable cells. As P AT N488I/WT CMTs had 37% fewer PI-positive nuclei (p = 6 3 10 À4 ; Figures 2F and 2G ), we deduced that N488I increased iPS-CM survival in CMT assays, but did not alter proliferation rates since BRDU+ and cyclin B1 expression were not increased in P AT N488I/WT iPS-CMs (Figures S2F and S2G) . Consistent with increased survival, P AT N488I/WT iPSCMs cultured routinely in standard tissue culture were 33% more viable at baseline (p = 0.03; Figure 2H , left panel) and after exposure to the cardiotoxic agent doxorubicin (p = 0.02; Figure S2H) . To determine whether the enhanced viability was due to inhibition of apoptosis, we measured caspase-3/7 cleavage in iPS-CMs. While overall cytotoxicity was decreased by 14% (p = 0.05; Figure 2H , middle panel) in P AT N488I/WT iPS-CMs consistent with PI staining, cell death by apoptosis was increased by 48% (p = 5 3 10 À6 ; Figure 2H , right panel). These results indicate that AMPK enhances twitch force in CMTs by inhibiting nonapoptotic cell death.
AMPK Regulates Metabolism by Transcript Regulation
Since PRKAG2 cardiomyopathy is associated with life-long AMPK changes, we speculated that transcript regulation would reflect mechanisms of the genetic disorder. We analyzed gene transcripts by RNA sequencing (RNA-seq) of iPS-CMs derived from P-S and TALEN isogenic cohorts ( Figure 3A ; Tables S3  and S4 ). We then performed unsupervised principle component analysis (PCA) of expression patterns to identify transcripts that separate cells within P-S and TALEN isogenic models (Figures 3B and 3C; Table S5 ). In both data sets, iPS-CMs with N488I were separated from controls by the first two principle components. PC 1 (PC1) included components of the cardiac sarcomere including myosin heavy chains (MYH6 and 7), myosin light chains (MYL3, 4, and 7) and thin filament components (TNNT2, TNNC1, and ACTC1). Moreover, PC1 contained genes associated with hypertrophy, such as ribosomal and translational transcripts (RPL41, EEF1A1, RPL37A1, and RPL37) and atrial-type natriuretic peptide (NPPA). PC 2 (PC2) contained gene transcripts involved in extracellular matrix (ECM) including collagens (COL11A1, COL1A1, COL3A1, COL1A2, and COL6A3) and ECM regulators (THBS2, LOX, BGN, and SERPINE2). PC2 also contained gene transcripts involved in cytoskeletal dynamics (ACTG2 and MYLK). Analysis of combined PC1 and PC2 transcripts by hierarchical clustering and illustrated in a heatmap ( Figures 3D and 3E ) confirmed shared gene expression patterns between iPS-CMs with PRKAG2-N488I. We proceeded to analyze differentially regulated gene transcripts from TALEN isogenic and P-S iPS-CM cohorts (Figure 4A) . We identified 623 differentially regulated transcripts in the P-S cohort and 1,660 in the TALEN isogenic cohort (Tables  S3 and S4 ). Differentially regulated transcripts were then analyzed by pathway analysis using Ingenuity Pathway Analysis (IPA) and ranked by Z score of enrichment. Like PCA, analysis of pathways enriched in both iPS-CM cohorts identified highly correlated (r = 0.69) pathways increased in both N488I iPS-CM models ( Figure 4B ). Key metabolic factors were enriched in iPS-CMs with PRKAG2-N488I including regulators of mitochondrial biogenesis and oxidative metabolism, such as PGC-1a, PPARg, PPARa, HNF-4a, and estrogen-related receptor a. Chemical agonists of these pathways were also identified, including guanidinopropionic acid (Reznick et al., 2007) , rosiglitazone (Lehmann et al., 1995) , and mono-(2-ethylhexyl) phthalate (Lovekamp-Swan et al., 2003). The N488I mutation increased RNA transcripts associated with increased microRNA activity that regulated myocyte differentiation (miR-124) (Cai et al., 2012) and pathologic cardiac hypertrophy (miR-1) (Ikeda et al., 2009) , as well as transcripts downstream of signaling by the insulin receptor family (INSR and IGF1R).
Because of increased glycogen storage, we analyzed glucose transporters and the rate-limiting enzymes that regulate glycogen content. Transcript data indicated that N488I mutation favored glycogen accumulation by coordinated regulation of key glucose handling transcripts. P AT N488I/WT iPS-CMs have increased insulin-dependent GLUT4 (SLC2A4; Figure 4C ) transcripts that are responsible for the majority of glucose transport in myocytes (Kraegen et al., 1993) , but reduced levels of GLUT1 (SLC2A1). In parallel, transcripts encoding glycogen synthase (GYS1) were increased in P AT N488I/WT iPS-CMs, while glycogen phosphorylase, the rate-limiting glycogen degradation enzyme, shifted from the more AMP-sensitive brain isoform (PYGB) to the less AMP-sensitive muscle isoform (PYGM) (Lehmann et al., 1995) (Figure 4D ).
To explore how AMPK regulates glycolysis and fatty acid oxidation, we analyzed transcripts in these pathways. P AT N488I/WT (H) IPS-CMs were cultured on tissue culture plates and analyzed for viability (left), cytotoxicity (middle), and apoptosis (right panel) (n R 6 replicates). The significance was assessed by Student's t test (A-C, E, F, and H) and the error bars are mean ± SEM (A-C, E, F, and H).
iPS-CMs exhibited an isoform switch in phosphofructokinase-1 (PFK-1), the rate-limiting step in glycolysis, to the less active muscle isoform from the liver isoform ( Figure 4E , left panel) and favored expression of PFK-2/FBPase PFKFB2 instead of PFKFB3. These changes implied that glycolysis would be less active in P AT N488I/WT iPS-CMs ( Figure 4E , right panel). Both CD36 and FABP3, genes that regulate fatty acid uptake into myocytes, were increased in P AT N488I/WT iPS-CMs ( Figure 4F ), a finding that is consistent with increased transcripts of regulators of mitochondrial biogenesis and oxidative phosphorylation, such as PGC1-1a itself ( Figure 4G ). Both mitochondrial transcripts encoded by nuclear DNA and in this organelle were also increased ( Figures 4H and 4I ).
To determine the functional relevance of transcript changes, we measured steady-state levels of intracellular metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/ MS), mitochondrial content and respiration, and glucose uptake and lactate production in conditioned media from TALEN isogenic iPS-CMs. We focused on pathways involved in glucose handling and oxidative metabolism and identified metabolites that correlated with AMPK activity, as determined by the level of p(T172)-AMPKa ( Figure 1C ). Among 224 metabolites detected ( Figure 5A ; Table S6 ), 70 were significantly increased (r > 0.67) and 78 were significantly decreased (r < À0.67) in P AT N488I/WT iPS-CMs. We analyzed metabolites associated with glucose handling first. Of four measured metabolites associated with 
-S iPS-CM Models
(A) Experimental design of RNA sequencing for purified P-S and TALEN isogenic iPS-CMs (pooled triplicates for P-S and duplicates of pooled triplicates for TALEN isogenic). (B-E) Unsupervised principle components analysis (PCA) of all TALEN isogenic (B) and P-S (C) iPS-CM gene transcripts separates cell populations by genotype by PC1 and PC2. The gene components of PC1 and PC2 are identified by official gene symbol. A heatmap displays 30 gene transcripts from all PC1 and PC2 components for TALEN isogenic (n = 6 pooled triplicates) (D) and P-S iPS-CMs (n = 4 pooled triplicates) (E). The gene transcripts and iPS-CMs were organized by hierarchical clustering. glycolysis with significant differences (p < 0.05), only glucose-6 phosphate was increased (r = 1.00) in P AT N488I/WT iPS-CMs. By contrast, the downstream glycolytic metabolites fructose-6-phosphate (r = À0.74), 1,3-bisphosphoglycerate (r = À0.83) and 3-phosphoglycerate (r = À0.72) were significantly decreased in P AT N488I/WT iPS-CMs ( Figure 5B ). Consistent with this mismatch between glucose uptake and glycolysis, the glycogen precursor glucose-1-phosphate was similarly increased (r = 0.94). To determine whether these steady-state levels reflected changes in the kinetics of glucose handling, we measured glucose uptake in conditioned media from P AT N488I/WT iPS-CMs compared to controls. Glucose uptake was increased by 8.3% (p = 0.008; Figure 5C , left panel) in parallel to glucose-6-phosphate, and lactate production was decreased by 8. similarly regulated glucose and lactate metabolism in iPS-CMs ( Figure S3B ). Metabolic intermediates associated with fatty acid oxidation identified by LC-MS/MS were increased, including carnitine (r = 0.91), C2-, C5-, and C8-long chain acylcarnitines (r = 0.99, 0.69, and 0.70, respectively) and long chain acyl-CoA (r = 0.77). Based on the increased transcripts encoding regulators of mitochondrial biogenesis (e.g., PGC-1a and PPARa), we suggest that increased mitochondrial content and function may account for increased steady-state levels of fatty acid intermediates. Indeed, both mitochondrial content and oxygen consumption were increased in P AT N488I/WT iPS-CMs compared to isogenic controls ( Figures 5D and S3A ).
AMPK Activation Inhibits TGFb Signaling by Inhibition of TGFb-2 Production In Vitro RNA-seq data revealed changes in gene expression that predicted inhibition of distinct signaling networks ( Figure 6A ).
Among these, we noted that N488I mutations reduced expression of transcript targets of TGFb signaling and other pathways implicated in cardiac fibrosis, including rictor (RICTOR) , thrombin (F2) (Carney et al., 1992) , angiotensinogen (AGT) (Rupé rez et al., 2003) , endothelin-1 (EDN1) (Widyantoro et al., 2010) , and the known cardiotoxic agent doxorubicin. Also, pathway regulators with functions downstream of non-canonical TGFb signaling were predicted to be inhibited, such as MAP kinase kinase kinase kinase 4 (MAP4K4) and MAP kinase signal-integrating kinase 1 (MKNK1). In addition, specific TGFb transcriptional targets including genes that regulate collagen crosslinking (LOXL1 and LOXL2), growth factor (CTGF), cytoskeleton (ACTN1, ACTA2, and FLNA), and signaling (LTBP2 and SMAD6) were reduced in P AT N488I/WT iPS-CMs ( Figure 6B ). As reduced activation of TGFb pathways could account for the unusual lack of fibrosis in PRKAG2 cardiomyopathy and the loss of integrity in the annulus fibrosis, we probed canonical TGFb signaling pathways by measuring SMAD2 phosphorylation at serine 465/457 in iPS-CMs. SMAD2 phosphorylation was inhibited in proportion to AMPK activation in both the TALEN isogenic iPS-CMs and with lenti-N488I and -R531Q to control for maturation and purity ( Figure 6C ). As decreased SMAD2 phosphorylation could reflect mechanisms upstream or downstream of the TGFb receptor, we remeasured SMAD2 phosphorylation after pre-treatment with the AMPK agonist A769662 in iPS-CMs treated with or without exogenous TGFb. Only A769662 pre-treatment without exogenous TGFb reduced SMAD2 phosphorylation by 28% (p = 0.03; Figure 6D , right image), which suggested a mechanism upstream of the receptor. Furthermore, TGFb precursor protein was reduced in iPS-CMs expressing either the N488I or R531Q mutation (p < 0.03; Figure 6E ).
We next determined the TGFb isoform that was regulated by AMPK by ELISA assays of conditioned culture media. P AT N488I/WT iPS-CMs and iPS-CMs with myocyte-specific lentiviral transduction of N488I or treated with A769662 dosedependently reduced levels of TGFb-2 ( Figure 6F ), but not TGFb-1 ( Figure S4A ). By contrast, we did not observe a significant relationship between AMPK activity and TGFb1 or TGFb2 transcript levels ( Figure S4B ). TGFb-3 was not expressed highly in iPS-CMs ( Figure S4B ). In summary, PRKAG2 mutations or A769662 that activate AMPK inhibit the production of TGFb precursor protein and leads to reduced TGFb-2 produced in iPS-CMs by post-transcriptional regulation.
AMPK Activation Inhibits TGFb-Regulated Transcripts In Vivo
We hypothesized that AMPK activation might provide a therapeutic strategy to inhibit pathological forms of cardiac remodeling that are associated with fibrosis, such as in HCM where TGFb signaling is increased (Teekakirikul et al., 2010) . We initially analyzed transcripts associated with fibrosis in RNA-seq data from pre-hypertrophic mice with PRKAG2 cardiomyopathy (Arad et al., 2003) with RNA-seq from wild-type and pre-hypertrophic HCM mice (MHC R403Q/+ ) (Geisterfer-Lowrance et al., 1996) . Similar to iPS-CM models, N488I mice had reduced expression of TGFb targets that are associated with fibrosis including extracellular matrix components and regulators ( Figure 7A ), which is in contrast to HCM mice. Human histopathology ( Figure 7B ) was consistent with these data. LV sections stained with Mason trichrome showed little fibrosis in a patient with PRKAG2 (N488I) cardiomyopathy compared to HCM (MYBPC3 +/À ). Therefore, while lifelong, constitutive AMPK activation leads to the PRKAG2 cardiomyopathy, a method to provide a tunable AMPK activation could achieve reduction in gene transcripts involved in fibrosis that are regulated by TGFb in vivo.
Next, we tested whether the AMPK agonist A769962 could prevent the development of hypertrophy and fibrosis in HCM mice. We treated 6-week-old pre-hypertrophic HCM mice with A769662, using a once instead of twice daily dose that did not change weight, blood pressure, or glucose (Cool et al., 2006) . A769662-treated HCM mice developed less hypertrophy (1.32 mm versus 1.55 mm, p = 0.04; Figure 7C ) and tissue fibrosis (5.02% compared to 6.85%, p = 0.002; Figure 7D ) compared to carrier-treated HCM mice. LV transcriptional analyses of A769662-treated HCM mice identified 2,768 differentially expressed genes compared to controls (Table S7) . Comparison of pathway analyses (IPA) of differentially expressed genes from the in vitro TALEN isogenic iPS-CM cohort with in vivo A769662-treated HCM mice, were highly correlated (r = 0.60). The activation states of multiple pathways were common to both, including TGFb that was the most negatively regulated pathway in vivo (Z score of À9.1; Figure 7E ). Moreover, A769662-treated HCM mice had markedly reduced cardiac expression of the same TGFb targets, including extracellular matrix components and regulators reduced in pre-hypertrophic N488I mice ( Figure 7F ). In addition, A769662-treatment reduced hypertrophic gene expression (NPPA and NPPB), normalized myosin isoform expression (MYH7/MYH6 ratios), and increased oxidative transcripts (e.g., PGC-1a and PPARa) in HCM hearts (Figures 7G and 7H) and in control hearts ( Figure S5 ).
DISCUSSION
AMPK coordinates metabolic sensing with a diverse group of energy-dependent cellular functions. The integration of biochemical, transcriptional, and functional data sets using human iPS-CMs, microtissues, and mouse models allowed us to deconvolute how mutations produce the phenotypes observed in PRKAG2 mutations. Our analyses of human iPS-CMs provide evidence that PRKAG2 mutations increase myocyte size in correlation with increased glycogen content and by activating AKT signaling, which is consistent with findings in PRKAG2 mouse models (Kim et al., 2014 ). We further demonstrate that regulation of glucose metabolism that results in glycogen accumulation by PRKAG2 mutations is due to coordinated changes in transcript abundance of key regulators of glucose handling. While other studies have defined the acute or chronic effects of AMPK activity on specific factors (Bultot et al., 2012; McGee et al., 2008) , this study is the first to define the transcriptional network that drives glycogen accumulation. For example, we find increased transcripts encoding glycogen synthase, and isoform shifts in glycogen phosphorylase, phosphofructokinase, and glucose transporters that parallel changes in steady-state metabolomics and glucose handling kinetics. On the other hand, we identify mitochondrial biogenesis factors increased, such as PGC-1a and PPARa, which parallel increased mitochondrial content and respiration. This pattern of metabolic remodeling is opposite to the changes associated with heart failure (Doenst et al., 2013) , which is reflected in the iPS-CMs by reduced transcripts associated with heart failure such as natriuretic peptides.
Unexpectedly, the metabolic and transcriptional changes induced by mutational activation of AMPK were associated with increased viability leading to increased twitch force in microtissues. These observations are consistent with in vivo studies that indicate increased AMPK activation can protect the heart from ischemic stress (Ofir et al., 2008) . Several mechanisms could account for the improved stress response, including increased AKT signaling observed here, glycogen content that would provide a ready supply of glucose, that is the preferred energy substrate in stressed myocytes (Ofir et al., 2008) , increased mitochondrial biogenesis, and activation of autophagy (Baskin and Taegtmeyer, 2011) . We recognize that the heightened viability and twitch force of mutant myocytes contrasts with the poor clinical courses of adult patients and mice with PRKAG2 cardiomyopathy (Murphy et al., 2005) . We suggest several observations that account for these differences. First, cardiac conduction system cells that were not modeled in these studies with PRKAG2 mutations progressively develop dysfunction and contribute substantially to in vivo phenotypes. Second, late-onset cardiac deficits of PRKAG2 mutations may not be well modeled in short-term tissue culture studies. Finally, as both embryonic myocytes and immature iPS-CMs routinely metabolize glucose for energy, these cells may have multiple adaptations to accommodate excess glucose and glycogen.
Unlike most other forms of LVH including HCM, PRKAG2 cardiomyopathy is distinguished by a remarkable absence of myocardial fibrosis. Attenuated TGFb signaling, that we identified in both iPS-CMs and mouse models of PRKAG2 cardiomyopathy, appears to account for the absence in fibrosis. While others have implicated AMPK in TGFb signaling in other tissues Lim et al., 2012) , we demonstrate that AMPK provides post-transcriptional regulation of TGFb-2, the most abundant TGFb isoform produced by iPS-CMs. We suggest that reduced TGFb-2 is also a contributing mechanism for ventricular pre-excitation arrhythmias that patients with PRKAG2 mutations can have. The annulus fibrosus, a band of connective tissue that insulates and prevents direct electrophysiologic connections between the atria and ventricles, develops from the embryonic cardiac cushions in response to TGFb-2 signals (Azhar et al., 2009) . Consistent with this TGFb-2 dependence, the annulus fibrosus is hypomorphic in PRKAG2 cardiomyopathy mouse models (Arad et al., 2003) and exhibits ventricular preexcitation and arrhythmias. By activating AMPK and reducing TGFb-2 production, we propose that PRKAG2 mutations that are selectively expressed in the heart may cause these developmental abnormalities. Finally, we show that the potential for harnessing AMPKdependent changes in TGFb signaling. We demonstrate that A769662 prevented fibrosis and cardiac hypertrophy in HCM mice. Consistent with these observations, others have reported that AMPK inhibition exacerbates cardiac remodeling and dysfunction after thoracic-aortic banding (Shimano et al., 2010) , while exercise promotes a reduction in cardiac fibrosis through AMPK-dependent mechanisms (Ma et al., 2015) . AMPK activation also increased expression of PGC-1a and PPARa, potentially providing an improved metabolic profile to HCM hearts. We suggest that pulsatile AMPK activation by direct agonists, such as A769662, has the potential to reduce myocardial fibrosis that accompanies adverse remodeling and promotes arrhythmias in HCM and other cardiomyopathies.
In conclusion, the critical linkages between metabolism and transcript regulation that we report provide novel insights into AMPK signaling and the pathophysiologic mechanisms for PRKAG2 cardiomyopathy. The global transcriptional remodeling of metabolism that favors glycogen accumulation instead of glycolysis and crosstalk between AMPK activity and TGFb signaling point to the complex roles by which altered AMPK activity impacts cardiac function. Small molecules that target AMPK activation are under development for several conditions, albeit with concerns that these may incite cardiomyopathy, similar to PRKAG2 mutations (Zaha and Young, 2012) . Our findings indicate the considerable potential for molecules that provide tailored and intermittent AMPK activation to attenuate fibrosis and adverse remodeling in cardiomyopathies and many other forms of heart disease.
EXPERIMENTAL PROCEDURES
IPSC Production, Differentiation, and PRKAG2 Lentivirus Patient samples were obtained after informed written consent using protocols approved by the Institutional Review Board of Partners HealthCare. Patientspecific iPSCs were produced from T cells (Loh et al., 2009 ) using STEMCCA lentivirus. IPSCs were screened for pluripotency markers ( Figures S1F-S1H) , copy number variants, karyotyping ( Figure S1G ), or virtual karyotyping using Illumina HumanOmniExpress-12 v1 arrays. iPSCs were maintained in feeder-free conditions and were differentiated to the CM lineage by small molecules (Lian et al., 2013) . IPS-CMs were purified using metabolic selection (Tohyama et al., 2013) and studied on day 30-40 after initiation of differentiation. Following differentiation, iPS-CM purity was determined by fluorescenceactivated cell sorting (FACS) analysis (>90% TnnT+) or by morphology. We amplified human PRKAG2 from a human iPS-CM cDNA library and inserted N488I and R531Q by site-directed mutagenesis (Agilent). We inserted sequence-verified PRKAG2 into the third generation lentivirus backbone pLenti (Addgene) and transduced iPS-CMs with MOI of 2.
TALEN Genome Editing TALE nucleases were designed to flank the targeted mutation at N488I in human PRKAG2 ( Figure S1A ) as previously described (Ding et al., 2013) . Briefly, TALEN genomic binding sites 15 bp in length (Table S1A) were chosen within 30 bp of the nucleotide change required during homologous recombination. The TALEN pair, along with a correction, 50-mer ssODN (Table S1A) that encoded the wild-type PRKAG2 sequence, were electroporated into P A N488I/WT iPSCs. GFP/RFP double-positive iPSCs were sorted ( Figure S1C ), expanded, and Sanger sequenced (Tables S1B and S2 ) to confirm either scarless correction to wild-type (P AT N488I/WT ) or in/dels that created a homozygous loss-of-function line (P AT KO/KO ). Genotypes were validated with RFLP analysis using restriction enzyme digest with MSE1 (NEB) (Figures S1D and S1E ). Experimental overview summarized in Figure S1B .
RNA-Sequencing and Computational Methods
Total RNA was isolated from day 30-40 iPS-CMs or 3-week-old mouse left ventricular tissue using TRIzol (Invitrogen). CDNA libraries were constructed using SuperScript III First-Strand Synthesis (Invitrogen). To reduce biologic variation among samples, cDNAs were pooled from at least biological triplicates for each sample and cDNA libraries were constructed using Nextera XT DNA Sample Preparation Kit (Illumina). Libraries were prepared and sequenced as described previously (Christodoulou et al., 2011) and were aligned with STAR (Engströ m et al., 2013) . Differentially regulated transcripts were analyzed, and transcript network analysis was generated through the use of IPA (QIAGEN). For hierarchical cluster analysis, we used Cluster 3.0.
Cardiac Microtissues and Microcontact Printing
CMTs were prepared as previously described (Boudou et al., 2012) . Micropatterned substrates were prepared as previously described (Tan et al., 2004) .
Cell Size and Flow Cytometry Assays
Cell size was measured by determining cell area on micropatterned surface using ImageJ (NIH). IPS-CMs were disassociated and analyzed by flow cytometry using a LSRFortessa analyzer (BD). Cell size was determined by analyzing forward scatter (FSC). Mitochondrial content was measured by staining iPSCMs with MitoTracker Green FM (Invitrogen) and analyzed using flow cytometry according to manufacturer's protocol. All FACS assays were done with at least biological triplicates.
LC-MS/MS Metabolomics and Other Metabolic Assays
Intracellular metabolites were extracted from day 30-40 iPS-CMs differentiated from TALEN isogenic iPSCs. All assays were done in biological triplicates. We performed metabolomic profiling using LC-MS/MS. For extended methods, see Supplemental Experimental Procedures. Seahorse XF24 (Seahorse Bioscience) was utilized to measure mitochondrial oxygen consumption according to manufacturers protocol. Glucose uptake was measured by biochemical methods from conditioned media using the glucose oxidase assay (Sigma), while lactate production was measured using a lactate dehydrogenase assay (Cayman). All metabolic assays were done with at least biological triplicates.
iPS-CM Viability and Cytotoxicity Assays
Day 30-40 iPS-CMs were cultured in two dimensional tissue culture formats and were stained for viability with ApoTox-Glo Assay (Promega). For doxorubicin (Tocris) experiments, iPS-CMs were exposed to doxorubicin (6 mM) for 12 hr prior to viability assay. For CMT viability experiments, propidium iodide (Invitrogen) was used according to manufacturer's protocol. PI+ nuclei were counted manually using ImageJ (NIH).
Western Blotting, Tissue Staining, and ELISA IPS-CM lysates were solubilized in RIPA buffer followed by western blotting using Cell Signaling antibodies: AMPKa Duet, ACC Duet, AKT Duet, SMAD2 Duet, cardiac actinin A (Abcam), TGFb, and GAPDH. ImageJ (NIH) was used to quantify western blot densitometries with at least three lanes per condition.
For imaging CMTs, we fixed CMTs with 4% PFA followed by staining with cardiac actinin A and DAPI. To measure conditioned media TGF-beta isoform production, we used Quantikine ELISA (R&D).
Mouse Protocols, Cardiac Imaging, and Fibrosis Quantification All mice were maintained and studied using protocols approved by the Animal Care and Use Committee of Harvard Medical School. Studies used male heterozygous HCM (MHC R403Q/+ ) mice that were in 129SvEv background and transgenic N488I that were in the FVB background. 6-week-old pre-hypertrophic HCM mice (n = 15 mice in each arm) were treated with either DMSO or A769662 (Cayman) subcutaneously once daily for 3 weeks at a dose of 30 mg/kg (Cool et al., 2006) . To accelerate hypertrophy, mice were treated with 1 mg/g Cyclosporine A (CsA; Novartis), which was administered via oral chow. We studied male mice that more consistently develop HCM than do female littermates. Fibrosis was quantified using analysis of Masson trichrome stained sections. Cardiac hypertrophy was measured using a Vevo 770 MicroImager (VisualSonics). For extended methods, see Supplemental Experimental Procedures. 
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